Logo image of GENT.OL

GENTIAN DIAGNOSTICS ASA (GENT.OL) Stock Price, Forecast & Analysis

Europe - Euronext Oslo - OSL:GENT - NO0010748866 - Common Stock

58.8 NOK
0 (0%)
Last: 1/16/2026, 4:10:29 PM

GENT.OL Key Statistics, Chart & Performance

Key Statistics
Market Cap906.70M
Revenue(TTM)172.52M
Net Income(TTM)42.78M
Shares15.42M
Float8.54M
52 Week High65.8
52 Week Low41
Yearly DividendN/A
Dividend Yield0.69%
EPS(TTM)2.73
PE21.54
Fwd PE21.67
Earnings (Next)N/A
IPO2016-12-14
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Supplies
GENT.OL short term performance overview.The bars show the price performance of GENT.OL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 2 4 6

GENT.OL long term performance overview.The bars show the price performance of GENT.OL in the last 1, 2 and 3 years. 1 year 2 years 3 years 10 20 30 40

The current stock price of GENT.OL is 58.8 NOK. In the past month the price increased by 1.73%. In the past year, price increased by 45.54%.

GENTIAN DIAGNOSTICS ASA / GENT Daily stock chart

GENT.OL Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to GENT.OL. When comparing the yearly performance of all stocks, GENT.OL is one of the better performing stocks in the market, outperforming 77.88% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

GENT.OL Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to GENT.OL. While GENT.OL has a great health rating, its profitability is only average at the moment.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GENT.OL Financial Highlights

Over the last trailing twelve months GENT.OL reported a non-GAAP Earnings per Share(EPS) of 2.73. The EPS increased by 2066.4% compared to the year before.


Industry RankSector Rank
PM (TTM) 24.8%
ROA 18.38%
ROE 21.18%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%22.54%
Sales Q2Q%27.94%
EPS 1Y (TTM)2066.4%
Revenue 1Y (TTM)17.42%

GENT.OL Forecast & Estimates

7 analysts have analysed GENT.OL and the average price target is 68.34 NOK. This implies a price increase of 16.22% is expected in the next year compared to the current price of 58.8.

For the next year, analysts expect an EPS growth of 59.41% and a revenue growth 31.13% for GENT.OL


Analysts
Analysts85.71
Price Target68.34 (16.22%)
EPS Next Y59.41%
Revenue Next Year31.13%

GENT.OL Ownership

Ownership
Inst Owners39.37%
Ins Owners2.6%
Short Float %N/A
Short RatioN/A

GENT.OL Competitors/Peers

The largest stocks on the EU markets in the "Health Care Supplies" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ESL.DE ESSILORLUXOTTICA 41.4 131.72B
1EL.MI ESSILORLUXOTTICA 39.4 125.37B
EL.PA ESSILORLUXOTTICA 39.45 125.51B
GBT.PA GUERBET 24.03 182.27M
ALCJ.PA CROSSJECT N/A 107.00M
AFME.PA AFFLUENT MEDICAL SA N/A 72.80M
PTP.DE PENTIXAPHARM HOLDING AG N/A 49.50M
SVS.MI SVAS BIOSANA SPA 6.38 45.36M
IVN.MI IVISION TECH SPA N/A 13.25M

Related stock screener links

About GENT.OL

Company Profile

GENT logo image Gentian Diagnostics ASA engages in the research, development, production, marketing, and distribution of immunoassays. The company is headquartered in Moss, Ostfold and currently employs 63 full-time employees. The company went IPO on 2016-12-14. The firm develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Company’s product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on clinical chemistry analysers: The Gentian Calprotectin Immunoassay, Cystatin C, NT-proBNP - Pre-launch, SARS-CoV-2 Ab Pre-Launch, Canine CRP and Beckman Coulter Customers. The firm is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.

Company Info

GENTIAN DIAGNOSTICS ASA

Bjornasveien 5

Moss OSTFOLD NO

Employees: 63

GENT Company Website

GENT Investor Relations

Phone: 4799339905

GENTIAN DIAGNOSTICS ASA / GENT.OL FAQ

Can you describe the business of GENTIAN DIAGNOSTICS ASA?

Gentian Diagnostics ASA engages in the research, development, production, marketing, and distribution of immunoassays. The company is headquartered in Moss, Ostfold and currently employs 63 full-time employees. The company went IPO on 2016-12-14. The firm develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Company’s product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on clinical chemistry analysers: The Gentian Calprotectin Immunoassay, Cystatin C, NT-proBNP - Pre-launch, SARS-CoV-2 Ab Pre-Launch, Canine CRP and Beckman Coulter Customers. The firm is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.


Can you provide the latest stock price for GENTIAN DIAGNOSTICS ASA?

The current stock price of GENT.OL is 58.8 NOK.


What is the dividend status of GENTIAN DIAGNOSTICS ASA?

GENTIAN DIAGNOSTICS ASA (GENT.OL) has a dividend yield of 0.69%. The yearly dividend amount is currently 0.


What is the ChartMill rating of GENTIAN DIAGNOSTICS ASA stock?

GENT.OL has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


What is GENTIAN DIAGNOSTICS ASA worth?

GENTIAN DIAGNOSTICS ASA (GENT.OL) has a market capitalization of 906.70M NOK. This makes GENT.OL a Small Cap stock.


Can you provide the ownership details for GENT stock?

You can find the ownership structure of GENTIAN DIAGNOSTICS ASA (GENT.OL) on the Ownership tab.